SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2003
BioTransplant Incorporated
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-28324 |
|
04-3119555 |
|
(State or other
jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
|
|
|
|
|
|
200
Boston Avenue |
|
|
|
02155 |
|
(Address of principal executive offices) |
|
|
|
(Zip Code) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (781) 393-8500 |
||||
|
|
||||
|
N/A |
||||
|
(Former name or former address, if changed since last report) |
||||
Item 5. Other Events.
On March 3, 2003, BioTransplant Incorporated issued a press release announcing that the Company received a Nasdaq Staff determination letter indicating that the Company’s securities will be delisted from the Nasdaq National Market at the opening of business on March 11, 2003. A copy of the press release announcing the receipt of the Nasdaq Staff determination letter is attached as Exhibit 99.1.
On March 14, 2003, BioTransplant Incorporated issued a press release announcing that the Company's common stock had begun trading on the OTC Bulletin Board effective March 14, 2003. A copy of the press release announcing that the Company's common stock had begun trading on the OTC Bulletin Board is attached as Exhibit 99.2.
On April 2, 2003, BioTransplant issued a press release announcing that the Company will host a conference call to provide an update on its previously filed voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code and on other corporate developments, including the status of its contract dispute with the Catholic University of Louvain. A copy of the press release announcing that the Company will host a conference call is attached as Exhibit 99.3.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: |
April 3, 2003 |
BIOTRANSPLANT INCORPORATED |
||
|
|
|
|
|
|
|
|
|
By: |
/s/ Donald B. Hawthorne |
|
|
|
|
|
Donald B. Hawthorne |
|
|
|
|
|
President and Chief Executive Officer |
|
3
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
Exhibit 99.1 |
|
Press Release dated March 3, 2003 |
|
|
|
|
|
Exhibit 99.2 |
|
Press Release dated March 14, 2003 |
|
|
|
|
|
Exhibit 99.3 |
|
Press Release dated April 2, 2003 |
|
|
|
|
4